Biontech Se ADR (BNTX)

$102.92 +0.80 (0.78%)
Market Cap 26.03B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.01
Volume 777,600
Avg Vol 1,129,104
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 88%
Beta 1.58
Analysts Strong Sell
Price Target $135.84

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
taxplanr
taxplanr Apr. 20 at 2:39 PM
C19 bioweapons legacy can't be hidden $BNTX $MRNA $PFE https://www.instagram.com/reel/DXU9oIDksxG/?igsh=enNxajZ2aW5iMWhh
0 · Reply
taxplanr
taxplanr Apr. 20 at 2:25 PM
Here's the safe and effective results $BNTX $MRNA $PFE https://www.instagram.com/reel/DXQ0TMuCMt7/?igsh=MWJsbHRlanZrd2Joaw==
0 · Reply
tkstockpicker
tkstockpicker Apr. 20 at 11:39 AM
$BNTX 🤔
0 · Reply
Lambo2
Lambo2 Apr. 20 at 5:12 AM
$BNTX
0 · Reply
CaasiNotwen
CaasiNotwen Apr. 19 at 4:04 AM
$BNTX https://www.nbcnews.com/health/cancer/pancreatic-cancer-mrna-vaccine-shows-lasting-results-early-trial-rcna331969
0 · Reply
taxplanr
taxplanr Apr. 18 at 11:01 AM
C19 clot shot stroke cover up $BNTX $MRNA $PFE https://www.instagram.com/reel/DW9mB2uAuMO/?igsh=MTFmZGEwbnZzdXd0Zg==
0 · Reply
SoYeonPicks
SoYeonPicks Apr. 18 at 3:05 AM
$BNTX starting my research here. What's the board's thought here on catalysts for 2026? I'm thinking base case of $130-$135 by EOY. Is that reasonable?
1 · Reply
birdflustocks
birdflustocks Apr. 17 at 2:58 PM
$BNTX $80 represents the $20 billion cash. $120 would include the $10 billion R&D expenses of the last 5 years. There are many positive results to consider, but any share price below $120 is just unreasonable.
1 · Reply
taxplanr
taxplanr Apr. 17 at 2:14 PM
Ivermectin Fenbendazole putting Cancer in remission in 3 months $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-7d9?utm_source=post-email-title&publication_id=1385328&post_id=194498283&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
htw7448
htw7448 Apr. 17 at 10:32 AM
$BNTX I’m fairly certain that two things will happen: - Market leaders such as Keytruda, with total annual sales of over 30 billion, will suffer significant losses. - Manufacturers of biosimilars in the cancer sector are in a quandary; they can only copy active ingredients that, at least in terms of cancer treatments, reflect a significantly inferior standard. Copying Keytruda (whose patent is due to expire soon) could possibly be less profitable.
0 · Reply
Latest News on BNTX
BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 11, 2026, 7:00 AM EDT - 9 days ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 18 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 24, 2026, 6:45 AM EDT - 27 days ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 3:39 PM EDT - 5 weeks ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 5 weeks ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 5 weeks ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Mar 10, 2026, 8:40 AM EDT - 5 weeks ago

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 5 weeks ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 5 weeks ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 5 weeks ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 5 weeks ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 5 weeks ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 5 weeks ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 7 weeks ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 2 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 2 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 3 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 3 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 4 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 4 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 4 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 4 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 4 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 4 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 5 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 5 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 5 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 5 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 5 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 6 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 6 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 6 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 6 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 6 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 7 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 7 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 7 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 7 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 7 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 7 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 8 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 8 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 8 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 8 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 9 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 9 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 9 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 9 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 9 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 9 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

taxplanr
taxplanr Apr. 20 at 2:39 PM
C19 bioweapons legacy can't be hidden $BNTX $MRNA $PFE https://www.instagram.com/reel/DXU9oIDksxG/?igsh=enNxajZ2aW5iMWhh
0 · Reply
taxplanr
taxplanr Apr. 20 at 2:25 PM
Here's the safe and effective results $BNTX $MRNA $PFE https://www.instagram.com/reel/DXQ0TMuCMt7/?igsh=MWJsbHRlanZrd2Joaw==
0 · Reply
tkstockpicker
tkstockpicker Apr. 20 at 11:39 AM
$BNTX 🤔
0 · Reply
Lambo2
Lambo2 Apr. 20 at 5:12 AM
$BNTX
0 · Reply
CaasiNotwen
CaasiNotwen Apr. 19 at 4:04 AM
$BNTX https://www.nbcnews.com/health/cancer/pancreatic-cancer-mrna-vaccine-shows-lasting-results-early-trial-rcna331969
0 · Reply
taxplanr
taxplanr Apr. 18 at 11:01 AM
C19 clot shot stroke cover up $BNTX $MRNA $PFE https://www.instagram.com/reel/DW9mB2uAuMO/?igsh=MTFmZGEwbnZzdXd0Zg==
0 · Reply
SoYeonPicks
SoYeonPicks Apr. 18 at 3:05 AM
$BNTX starting my research here. What's the board's thought here on catalysts for 2026? I'm thinking base case of $130-$135 by EOY. Is that reasonable?
1 · Reply
birdflustocks
birdflustocks Apr. 17 at 2:58 PM
$BNTX $80 represents the $20 billion cash. $120 would include the $10 billion R&D expenses of the last 5 years. There are many positive results to consider, but any share price below $120 is just unreasonable.
1 · Reply
taxplanr
taxplanr Apr. 17 at 2:14 PM
Ivermectin Fenbendazole putting Cancer in remission in 3 months $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-7d9?utm_source=post-email-title&publication_id=1385328&post_id=194498283&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
htw7448
htw7448 Apr. 17 at 10:32 AM
$BNTX I’m fairly certain that two things will happen: - Market leaders such as Keytruda, with total annual sales of over 30 billion, will suffer significant losses. - Manufacturers of biosimilars in the cancer sector are in a quandary; they can only copy active ingredients that, at least in terms of cancer treatments, reflect a significantly inferior standard. Copying Keytruda (whose patent is due to expire soon) could possibly be less profitable.
0 · Reply
htw7448
htw7448 Apr. 17 at 10:25 AM
$BNTX
0 · Reply
htw7448
htw7448 Apr. 17 at 10:23 AM
$BNTX Biontech will begin to transform the pharmaceutical industry in 2026. It will tackle cancer treatment with revolutionary active ingredients and approaches. If you look at the clinical trial data for these active ingredients, the individual components alone are already incredibly powerful. The overall potential is, of course, significantly greater when combined with personalised diagnostics and a modular treatment approach. We’re talking about nothing less than a revolution. Now you can see what it currently costs to invest in a game-changer. Ridiculous...
0 · Reply
outlawinvestor1
outlawinvestor1 Apr. 17 at 12:51 AM
$BNTX will it break through the $125 wall this time?
0 · Reply
SqueezeCitronShorts
SqueezeCitronShorts Apr. 16 at 7:01 PM
Watch ticker PN for a massive squeeze. PN has only 1.2 million shares outstanding and they announced a BUYBACK recently on that tiny float. If they execute this buyback, PN could see a MASSIVE short squeeze. $AMC $GME $BNTX $NVAX craze.
0 · Reply
taxplanr
taxplanr Apr. 16 at 12:54 PM
mRNA testimonial from Japan $PFE $BNTX $MRNA https://www.instagram.com/p/DXKcpNMn5V1/?igsh=MWx0aDBsMjI4OGF6dw==
0 · Reply
TS4
TS4 Apr. 15 at 6:51 PM
$VXRT $BNTX More to come with mRNA versus VAAST pill. One can be 100% sure, that Biontech founders did know about these requirements by a judge before leaving the company. Sanofi does know as well. RFK too.
2 · Reply
wheresdannynow
wheresdannynow Apr. 15 at 4:28 PM
Immunotherapy momentum building. $MRNA $BNTX $MRK pushing oncology + platform plays forward. $BIOV.CSE $BVAXF sitting in that rotation as smaller caps start catching bids. Platform + data + timing. These are the ones that can run fast.
0 · Reply
htw7448
htw7448 Apr. 15 at 3:10 PM
$BNTX new potential event on AACR Annual Meeting: April 17-22, 2026. The presentation headlines still pending :P.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 15 at 12:09 PM
$SPY $GSK $PFE $MRNA $BNTX
0 · Reply
taxplanr
taxplanr Apr. 15 at 12:14 AM
Cancer Free in 16 months with Ivermectin and Mebendazole $BNTX $MRNA $MRK $BMY https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-f6b?utm_source=post-email-title&publication_id=1385328&post_id=194141941&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
htw7448
htw7448 Apr. 14 at 3:19 PM
$BNTX 100$ is just the starter for Biontech this year
0 · Reply
taxplanr
taxplanr Apr. 14 at 1:56 PM
$BNTX $MRNA $PFE just can't shake the bioweapon narrative https://x.com/elonmusk/status/2043276162487759115?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E2043276162487759115%7Ctwgr%5E6b4f5fbe734b6410ad016d32f642a0cf08cb78cd%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fchildrenshealthdefense.org%2Fdefender%2Felon-musk-covid-vaccine-injury-former-pfizer-official-shots-likely-killed-thousands-germany%2F
0 · Reply